Skip to Main content Skip to Navigation
Journal articles

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis

Abstract : AbstractDeregulated expression of heat shock proteins (HSPs) encoding genes is frequent in multiple myeloma. HSPs, which are molecular chaperones involved in protein homeostasis pathways, have emerged recently as promising therapeutic targets. Using human myeloma cell lines and primary myeloma cells belonging to various molecular groups, we tested the efficacy of HSP90, HSP70, and heat shock factor 1 (HSF1) inhibitors alone or associated with current antimyeloma drugs. We report here that KNK-437 (an inhibitor of HSF1) and bortezomib have additive effects on apoptosis induction in cells belonging to groups with bad prognosis.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-01237704
Contributor : Bmc Bmc <>
Submitted on : Thursday, December 3, 2015 - 4:15:50 PM
Last modification on : Friday, June 19, 2020 - 3:08:41 AM
Long-term archiving on: : Saturday, April 29, 2017 - 5:14:06 AM

Files

13045_2015_Article_135.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Sophie Bustany, Julie Cahu, Géraldine Descamps, Catherine Pellat-Deceunynck, Brigitte Sola. Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis. Journal of Hematology and Oncology, BioMed Central, 2015, 8 (1), pp.40. ⟨10.1186/s13045-015-0135-3⟩. ⟨inserm-01237704⟩

Share

Metrics

Record views

336

Files downloads

247